Veristat Growth and Service Demand Drive Expansion: Veristat to Move Corporate Headquarters

Veristat will Move Corporate Headquarters to Southborough, MA This Summer

HOLLISTON, MA – Veristat, a full service Clinical Research Organization (CRO), announced today that it plans to move the Company's corporate headquarters from Holliston (Massachusetts) to Southborough (Massachusetts) this coming summer. The move is driven by Veristat's rapid growth in response to the increased demand for full-service clinical research offerings by its pharmaceutical and biotechnology clients.

"Veristat has experienced a fundamental shift over the past few years, where clients who previously partnered with us to provide a single core service offering now want us to manage their entire trial through to regulatory submissions," commented Patrick Flanagan, Chief Executive Officer of Veristat, "We are increasingly bringing on more full-service projects. In response, we are growing the organization in order to ensure that our clients receive the dedicated attention and scientific-based expertise that they have come to expect from Veristat."

Over the past two years, Veristat has grown its employee base by more than 300%, and in 2015 has added over 30 new employees to keep up with client demand. 

I congratulate Veristat on its growth and move," commented David Valacer, Chief Medical Officer of Molecular Templates, "Veristat has been a valuable partner to my organization, helping us launch a new clinical study into patients. I wish Veristat much future success in helping firms like mine bring novel therapies to patients who need them.

Veristat plans to move its Corporate Headquarters to 118 Turnpike Road (Route 9 Eastbound) in Southborough, Massachusetts where it will occupy the second floor comprising 33,000 sf of Class A space. In addition to its corporate headquarters office, Veristat has additional offices in Cambridge, MA and Montreal, Canada. The Company has plans to expand its current operations in the San Francisco Bay Area with a new office opening soon.

"Barbara and I founded Veristat more than 20 years ago with a core focus in providing Biostatistics and Medical Writing services," stated John Balser, PhD, President of Veristat, "I see our recent and continued growth as the next step in providing our clients with great service and expanded capabilities for the design, conduct, analysis and results reporting of their clinical studies."

About Veristat
Veristat, LLC is an innovative full-service, science-focused clinical research organization (CRO) with over 20 years of expertise in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive clinical development services, including biostatistics, statistical programming, medical writing, clinical monitoring and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat's unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark. For more information, please visit www.veristat.com.

Veristat Contact:
Gillian Dellacioppa, Marketing Director
[email protected] or 508-306-6336

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.